Real-world effectiveness of onabotulinumtoxinA as first-line treatment in chronic migraine and sequential transition to anti-CGRP monoclonal antibodies: a retrospective multicenter study.

Kępczyńska K et al.

NCBI PubMed Central · Papers · License: Open Access

data protection law GDPR

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 295198
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.